Top Story

Younger age associated with genetic alterations in lung adenocarcinoma

March 22, 2017

Oncogenic genetic alterations occurred more frequently among patients aged younger than 40 years with lung adenocarcinoma than older patients, according to results of a retrospective study.

“Young patients with adenocarcinoma may be prime candidates for precision medicine strategies, because they tend to have more genetic alterations that can be treated with existing targeted therapies, leading to a compatible prognosis,” Kosuke Tanaka, MD, from the department of thoracic oncology at Aichi Cancer Center Hospital in Japan, and colleagues wrote.

AMA urges members of Congress to oppose American Health Care Act

March 22, 2017
The American Medical Association today released a letter to members of Congress urging them to oppose the American Health Care Act, citing projections that it will cost…
Meeting News Coverage

Dermatologist: Many Hispanics don't believe they're at risk for skin cancer

March 22, 2017
Although many Hispanic people believe they are not at risk for skin cancer, the population is more likely to be diagnosed with the disease in more advanced stages…
In the Journals

ASCO issues global guidance on HPV vaccination to prevent cervical cancer

March 22, 2017
The American Society of Clinical Oncology, or ASCO, has released the first guideline on primary prevention of cervical cancer that accommodate multiple regions of the…

ACP: New amendments to AHCA ‘even less acceptable’

March 22, 2017
ACP recently sent a letter to the Congressional leadership in strong opposition of the manager’s amendments to the American Health Care Act, arguing that several…
More News Headlines »

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Meeting News

VIDEO: SUSTAIN trial brings potential ‘disease-modifying’ treatment to sickle cell

February 6, 2017
More »
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies


Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Current Issues
View the Current Issue
HemOnc Today